<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">PI</journal-id><journal-title-group><journal-title>Pharmacy Information</journal-title></journal-title-group><issn pub-type="epub">2160-441X</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/PI.2020.92008</article-id><article-id pub-id-type="publisher-id">PI-34666</article-id><article-categories><subj-group subj-group-type="heading"><subject>PI20200200000_67486543.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  内源性胰腺
  β细胞再生的研究进展
  Research Progress of Endogenous Pancreatic 
  β Cell Regeneration
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>崔</surname><given-names>雪婷</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>陆勇</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>中国药科大学，江苏省新药筛选重点实验室，江苏 南京;广东药科大学，新药研发中心，广东 广州</addr-line></aff><aff id="aff2"><addr-line>中国药科大学，江苏省新药筛选重点实验室，江苏 南京</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>28</day><month>02</month><year>2020</year></pub-date><volume>09</volume><issue>02</issue><fpage>53</fpage><lpage>56</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   糖尿病是一种进行性的代谢性疾病，其主要特征是血糖持续升高。目前认为内源性胰腺β细胞再生是治疗糖尿病的一种潜在策略。β细胞再生主要是指机体内残存的β细胞增殖或将其他类型细胞转分化为β细胞两个方面。因此，本文将以内源性β细胞再生的最新研究进展进行综述，为糖尿病的治疗提供新的治疗手段。 Diabetes is a kind of progressive metabolic disease, which is characterized by the continuous in-crease of blood glucose. Endogenous pancreatic β-cell regeneration is currently considered a potential strategy for the treatment of diabetes. Beta cell regeneration mainly refers to two aspects: the proliferation of beta cells remaining in the body or the transdifferentiation of other types of cells into beta cells. Therefore, this article will review the latest research progress of endogenous β-cell regeneration, and provide new treatments for the treatment of diabetes. 
  
 
</p></abstract><kwd-group><kwd>糖尿病，细胞增殖，转录因子，潜在药物，胰岛β细胞, Diabetes</kwd><kwd> Cell Proliferation</kwd><kwd> Transcription Factors</kwd><kwd> Potential Drugs</kwd><kwd> Islet Beta Cells</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>内源性胰腺β细胞再生的研究进展<sup> </sup></title><p>崔雪婷<sup>1</sup>，张陆勇<sup>1,2*</sup></p><p><sup>1</sup>中国药科大学，江苏省新药筛选重点实验室，江苏 南京</p><p><sup>2</sup>广东药科大学，新药研发中心，广东 广州</p><disp-formula id="hanspub.34666-formula68"><graphic xlink:href="//html.hanspub.org/file/4-1710213x5_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2020年3月1日；录用日期：2020年3月16日；发布日期：2020年3月23日</p><disp-formula id="hanspub.34666-formula69"><graphic xlink:href="//html.hanspub.org/file/4-1710213x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>糖尿病是一种进行性的代谢性疾病，其主要特征是血糖持续升高。目前认为内源性胰腺β细胞再生是治疗糖尿病的一种潜在策略。β细胞再生主要是指机体内残存的β细胞增殖或将其他类型细胞转分化为β细胞两个方面。因此，本文将以内源性β细胞再生的最新研究进展进行综述，为糖尿病的治疗提供新的治疗手段。</p><p>关键词 :糖尿病，细胞增殖，转录因子，潜在药物，胰岛β细胞</p><disp-formula id="hanspub.34666-formula70"><graphic xlink:href="//html.hanspub.org/file/4-1710213x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/4-1710213x8_hanspub.png" /> <img src="//html.hanspub.org/file/4-1710213x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>糖尿病(Diabetes mellitus, DM)是一种由多病因引起的慢性疾病，影响着全球数百万人的生活质量。国际糖尿病联合会的报告显示，2019年全球糖尿病患者人数达到4.63亿，而在中国20至79岁成年人中糖尿病的发病人数已达到1.164亿。在1型糖尿病的早期阶段和2型糖尿病的进展中，胰腺β细胞受到了破坏，进而导致血糖升高 [<xref ref-type="bibr" rid="hanspub.34666-ref1">1</xref>]。因此，β细胞的再生是恢复糖尿病患者β细胞丢失的一种潜在的治疗策略。</p><p>β细胞再生是指通过内源性再生或外源性补充。近年来的研究表明，内源性再生主要包括刺激体内现有的β细胞增殖、将其他胰腺细胞重编程进而分化成β细胞、离体诱导多能干细胞分化成新的β细胞或通过基因工程手段等 [<xref ref-type="bibr" rid="hanspub.34666-ref2">2</xref>]。而外源性补充包括胰岛移植等。虽然胰岛移植在临床上取得一定的成效，但由于供体来源和移植后的排斥反应限制了其应用和发展。因此，内源性β细胞再生一直成为糖尿病领域的研究热点，对于开发糖尿病的治疗方法具有深远的意义。本文就内源性β细胞再生的最新策略和途径进行综述。</p></sec><sec id="s4"><title>2. 刺激现有的β细胞增殖</title><p>内源性β细胞再生的重要策略之一是刺激现有的β细胞增殖。以前的研究表明，胰腺β细胞在胎儿和新生儿阶段的增殖能力较强，而随着时间的推移，这种增殖能力逐渐下降。但当机体处于生理或病理状态下，如胚胎发育、妊娠、糖尿病，会发生适应性的β细胞增殖。在小鼠成年后或经过胰腺切除术后，现有的β细胞仍具有再生能力，是新的β细胞的主要来源 [<xref ref-type="bibr" rid="hanspub.34666-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.34666-ref4">4</xref>]。高通量化学筛选发现了多种刺激β细胞增殖的潜在药物 [<xref ref-type="bibr" rid="hanspub.34666-ref5">5</xref>]，如DYRK1A抑制剂，通过抑制钙调神经磷酸酶/NFAT/DYRK1A信号转导而增加β细胞的增殖 [<xref ref-type="bibr" rid="hanspub.34666-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.34666-ref7">7</xref>]。骨保护素和地诺单抗通过抑制NF-κB配体受体激活物途径从而刺激人β细胞增殖 [<xref ref-type="bibr" rid="hanspub.34666-ref8">8</xref>]。</p></sec><sec id="s5"><title>3. 其他胰腺细胞重编程为β细胞</title><p>在胚胎发育过程中，胰腺β细胞是由多功能胰腺祖细胞在特定的转录因子调控下形成的。胰腺上皮细胞和Ngn3阳性胰腺细胞被认为是β细胞的祖细胞。在啮齿类动物模型中，当胰岛遭到破坏时，它们可以分化为β细胞。在本节中，将主要介绍通过转录因子对内分泌细胞分化的调节作用和药物刺激将非β细胞转化为β细胞的研究进展。</p><sec id="s5_1"><title>3.1. 转录因子对内分泌细胞分化的调节作用</title><p>胚胎胰腺β细胞的发育受到胰腺相关的特定转录因子的调控 [<xref ref-type="bibr" rid="hanspub.34666-ref9">9</xref>]。在早期胰腺芽发育过程中，多能胰腺祖细胞的维持和分化受胰腺转录因子Gata4/6、Foxa1/2、Pdx1、Ptf1a、Mnx1、Sox9、Nkx6.1和Hnf1β的调控，若其中任何一种转录因子的缺失都会损害胰腺芽的形成 [<xref ref-type="bibr" rid="hanspub.34666-ref10">10</xref>]。此外，Pdx1或Ptf1a在内胚层的异位表达可诱导异位胰腺芽的形成 [<xref ref-type="bibr" rid="hanspub.34666-ref11">11</xref>]。早期内分泌祖细胞来源于内分泌/导管双能祖细胞，其分化是由神经基因3 (Ngn3)的表达来启动的。而Ngn3缺乏的小鼠不能产生内分泌细胞，但导管增大，Ngn3异位表达将会引导胰腺祖细胞转向内分泌的命运。因此，Ngn3是胰岛细胞分化所必需的 [<xref ref-type="bibr" rid="hanspub.34666-ref12">12</xref>]。</p><p>内分泌的发育需要其他的内分泌前体细胞转录因子的参与，如Isl1、Neurod1、Pax6、Mafb、Nkx2.2和Rfx6。而这些转录因子由Ngn3所激活，并参与内分泌细胞系的分化 [<xref ref-type="bibr" rid="hanspub.34666-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.34666-ref14">14</xref>]。Pax4和ARX通过交叉抑制作用调控胰岛细胞的特异性，Pax4和ARX分别促进胰岛祖细胞分化为β/δ或α/PP细胞 [<xref ref-type="bibr" rid="hanspub.34666-ref15">15</xref>]。α细胞的阳性转录因子谱包括Arx、Mafb、Rfx6、Nkx2.2、Neurod1和Pax6，而β细胞的阳性转录因子谱为Nkx2.2、Pax4/6、Pdx1、Nkx6.1和Mafα。</p></sec><sec id="s5_2"><title>3.2. 刺激β细胞转化的潜在药物</title><sec id="s5_2_1"><title>3.2.1. γ-氨基丁酸</title><p>γ-氨基丁酸(GABA)是由β细胞中的谷氨酸经谷氨酸脱羧酶(GAD)合成的，是一种作用于胰岛的细胞外信号分子。研究表明，长期的GABA处理可能会诱导表达胰高血糖素的α细胞转变为功能性的产生胰岛素的β样细胞 [<xref ref-type="bibr" rid="hanspub.34666-ref16">16</xref>]。此外，用GABA处理移植的人胰岛会导致α细胞丢失，并伴随β样细胞的增加，这也暗示着人类中存在α到β样细胞的转化过程。然而，GABA介导的α细胞转化为β细胞的机制还有待于进一步阐明 [<xref ref-type="bibr" rid="hanspub.34666-ref17">17</xref>]。</p></sec><sec id="s5_2_2"><title>3.2.2. 青蒿素</title><p>抗疟剂药物青蒿素可能是α细胞向β细胞转化的潜在的激活剂。研究表明，青蒿素可以损伤α细胞的特性，并通过诱导ARX由细胞核向细胞质的转移而抑制ARX的表达 [<xref ref-type="bibr" rid="hanspub.34666-ref18">18</xref>]。此外，这些抗疟药物的靶蛋白是桥尾蛋白，而这些分子的作用机制又取决于GABAA受体信号的增强。然而，有研究发现，蒿甲醚不能促进原代α细胞转分化为β细胞，而且可使β细胞的Ins 2表达降低100倍以上，抑制对葡萄糖的摄取，消除β细胞对葡萄糖的钙反应和胰岛素分泌，所以蒿甲醚可诱导胰岛内分泌细胞的脱分化 [<xref ref-type="bibr" rid="hanspub.34666-ref19">19</xref>]。青蒿素对β细胞再生的研究有待于进一步去验证。</p></sec><sec id="s5_2_3"><title>3.2.3. 饮食治疗</title><p>与胰腺发育过程类似，当小鼠经过4天的禁食模拟饮食(Fasting-Mimicking Diet, FMD)后可以诱导Sox17和Pdx1的逐步表达，然后由Ngn3驱动产生分泌胰岛素的β细胞。FMD循环恢复2型和1型糖尿病小鼠模型的胰岛素分泌和葡萄糖稳态 [<xref ref-type="bibr" rid="hanspub.34666-ref20">20</xref>]。因此，FMD能促进胰腺细胞的重新编程，以恢复1型糖尿病患者胰岛的胰岛素生成，并逆转小鼠模型的1型和2型糖尿病的表型。</p></sec></sec></sec><sec id="s6"><title>4. 小结</title><p>目前，内源性β细胞再生的研究已取得了一定的成果，从而可以从根本上解决糖尿病患者β细胞衰竭的问题，为糖尿病的治疗提供了有效的手段。但新胰岛的形成是一个复杂而动态的过程，新的胰岛可能包含不同的细胞类型，甚至存在中间的过渡态细胞。内源性β细胞再生作为糖尿病的替代疗法，虽然前景广阔，但仍需要进一步去研究完善。随着生物信息学的发展，相信将来一定能解决以上疑问，为糖尿病的治疗带来新的希望。</p></sec><sec id="s7"><title>文章引用</title><p>崔雪婷,张陆勇. 内源性胰腺β细胞再生的研究进展Research Progress of Endogenous Pancreatic β Cell Regeneration[J]. 药物资讯, 2020, 09(02): 53-56. https://doi.org/10.12677/PI.2020.92008</p></sec><sec id="s8"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.34666-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Nidheesh, D., Abhay, S., Neha, P., et al. (2015) Swertisin an Anti-Diabetic Compound Facilitate Islet Neogenesis from Pancreatic Stem/Progenitor Cells via p-38 MAP Kinase-SMAD Pathway:An In-Vitro and In-Vivo Study. PLoS ONE, 10, e0128244. &lt;br&gt;https://doi.org/10.1371/journal.pone.0128244</mixed-citation></ref><ref id="hanspub.34666-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Zhou, Q. and Melton, D.A. (2018) Pancreas Regeneration. Nature, 557, 351-358.  
&lt;br&gt;https://doi.org/10.1038/s41586-018-0088-0</mixed-citation></ref><ref id="hanspub.34666-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Cano, D.A., Rulifson, I.C., Heiser, P.W., et al. (2008) Regulated Beta-Cell Regeneration in the Adult Mouse Pancreas. Diabetes, 57, 958-966. &lt;br&gt;https://doi.org/10.2337/db07-0913</mixed-citation></ref><ref id="hanspub.34666-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Dor, Y., Brown, J., Martinez, O.I. and Melton, D.A. (2004) Adult Pancreatic Beta-Cells Are Formed by Self-Duplication Rather than Stem-Cell Differentiation. Nature, 429, 41-46. &lt;br&gt;https://doi.org/10.1038/nature02520</mixed-citation></ref><ref id="hanspub.34666-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Walpita, D., Hasaka, T., Spoonamore, J., et al. (2011) A Human Islet Cell Culture System for High-Throughput Screening. Journal of Biomolecular Screening, 17, 509. &lt;br&gt;https://doi.org/10.1177/1087057111430253</mixed-citation></ref><ref id="hanspub.34666-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Wang, P., Alvarez-Perez, J.C., Felsenfeld, D.P., et al. (2015) A High-Throughput Chemical Screen Reveals that Harmine-Mediated Inhibition of DYRK1A Increases Human Pancre-atic Beta Cell Replication. Nature Medicine, 21, 383-388. &lt;br&gt;https://doi.org/10.1038/nm.3820</mixed-citation></ref><ref id="hanspub.34666-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Dirice, E., Wal-pita, D., Vetere, A., et al. (2016) Inhibition of DYRK1A Stimulates Human Beta-Cell Proliferation. Diabetes, 65, 1660-1671. &lt;br&gt;https://doi.org/10.2337/db15-1127</mixed-citation></ref><ref id="hanspub.34666-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Kondegowda, N., Fenutria, R., Pollack, I., et al. (2015) Os-teoprotegerin and Denosumab Stimulate Human Beta Cell Proliferation through Inhibition of the Receptor Activator of NF-κB Ligand Pathway. Cell Metabolism, 22, 77-85. 
&lt;br&gt;https://doi.org/10.1016/j.cmet.2015.05.021</mixed-citation></ref><ref id="hanspub.34666-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Hang, Y. and Stein, R. (2011) MafA and MafB Activity in Pan-creatic β Cells. Trends in Endocrinology &amp; Metabolism, 22, 364-373. &lt;br&gt;https://doi.org/10.1016/j.tem.2011.05.003</mixed-citation></ref><ref id="hanspub.34666-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Romer, A.I. and Sussel, L. (2015) Pancreatic Islet Cell Develop-ment and Regeneration. Current Opinion in Endocrinology &amp; Diabetes and Obesity, 22, 255-264. &lt;br&gt;https://doi.org/10.1097/MED.0000000000000174</mixed-citation></ref><ref id="hanspub.34666-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Afelik, S., Chen, Y.L. and Pieler, T. (2006) Combined Ectopic Expression of Pdx1 and Ptf1a/p48 Results in the Stable Conversion of Posterior Endoderm into Endocrine and Exocrine Pancreatic Tissue. Genes &amp; Development, 20, 1441-1446.  
&lt;br&gt;https://doi.org/10.1101/gad.378706</mixed-citation></ref><ref id="hanspub.34666-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Oropez, D. and Horb, M. (2012) Transient Expression of Ngn3 in Xenopusendoderm Promotes Early and Ectopic Development of Pancreatic Beta and Delta Cells. Genesis, 50, 271-285. &lt;br&gt;https://doi.org/10.1002/dvg.20828</mixed-citation></ref><ref id="hanspub.34666-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Gradwohl, G., Dierich, A., Lemeur, M., et al. (2000) Neurogenin3 Is Required for the Development of the Four Endocrine Cell Lineages of the Pancreas. Proceedings of the National Academy of Sciences, 97, 1607-1611. 
&lt;br&gt;https://doi.org/10.1073/pnas.97.4.1607</mixed-citation></ref><ref id="hanspub.34666-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Jeon J., Correa-Medina, M., Ricordi, C., Edlund, H. and Diez, J.A. (2009) Endocrine Cell Clustering during Human Pancreas Development. Journal of Histochemistry and Cytochemistry, 57, 811-824.  
&lt;br&gt;https://doi.org/10.1369/jhc.2009.953307</mixed-citation></ref><ref id="hanspub.34666-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Napolitano, T., Avolio, F., Courtney, M., et al. (2015) Pax4 Acts as a Key Player in Pancreas Development and Plasticity. Seminars in Cell &amp; Developmental Biology, 44, 107-114. &lt;br&gt;https://doi.org/10.1016/j.semcdb.2015.08.013</mixed-citation></ref><ref id="hanspub.34666-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Ben-Othman, N., Vieira, A., Courtney, M., et al. (2017) Long-Term GABA Administration Induces Alpha Cell-Mediated Beta-like Cell Neogenesis. Cell, 168, 73-85. &lt;br&gt;https://doi.org/10.1016/j.cell.2016.11.002</mixed-citation></ref><ref id="hanspub.34666-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Weir, G.C. and Bonner-Weir, S. (2017) GABA Signaling Stimu-lates β Cell Regeneration in Diabetic Mice. Cell, 168, 7-9. &lt;br&gt;https://doi.org/10.1016/j.cell.2016.12.006</mixed-citation></ref><ref id="hanspub.34666-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Li, J., Casteels, T., Frogne, T., et al. (2017) Artemisinins Target GABAA Receptor Signaling and Impair α Cell Identity. Cell, 168, 86-100.e15. &lt;br&gt;https://doi.org/10.1016/j.cell.2016.11.010</mixed-citation></ref><ref id="hanspub.34666-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Talitha, V.D.M., Lee, S., Noordeloos, E., et al. (2017) Artemether Does Not Turn α Cells into β Cells. Cell Metabolism, 27, 218-225.e4. &lt;br&gt;https://doi.org/10.1016/j.cmet.2017.10.002</mixed-citation></ref><ref id="hanspub.34666-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Cheng, C.W., Villani, V., Buono, R., et al. (2017) Fast-ing-Mimicking Diet Promotes Ngn3-Driven β-Cell Regeneration to Reverse Diabetes. Cell, 168, 775-788.e12. &lt;br&gt;https://doi.org/10.1016/j.cell.2017.01.040</mixed-citation></ref></ref-list></back></article>